#United States #New York #Securities Fraud #Rosen Law Firm #Hims & Hers

Hims & Hers Health Investors: Class Action Lawsuit Opportunity

Overview

The Rosen Law Firm, known for its global focus on investor rights, has announced an important reminder for investors of Hims & Hers Health, Inc. (NYSE: HIMS). If you purchased common stock between April 29, 2025, and June 23, 2025, and experienced a loss exceeding $100,000, you may be eligible to participate in a securities fraud class action lawsuit. The lead plaintiff deadline is set for August 25, 2025, making it crucial for impacted investors to take action promptly.

Key Reasons to Act

Participating in this class action presents an opportunity for investors to seek compensation without incurring out-of-pocket expenses. Rosen Law Firm operates under a contingency fee basis, which means that legal fees are only covered if the case is successful. This financial structure allows investors to recover losses without upfront costs, making it accessible and appealing for those who qualify.

How to Participate

Investors wishing to join the Hims class action should visit Rosen Legal's website. Alternatively, they can reach out to Phillip Kim, Esq. at the Rosen Law Firm by calling toll-free 866-767-3653 or emailing [email protected] for more information. Ensure that your application to serve as lead plaintiff is submitted by the aforementioned deadline to be considered.

Understanding the Allegations

The crux of the lawsuit centers around claims that during the specified Class Period, Hims & Hers Health, Inc. made false and misleading statements regarding their operations, particularly in connection with a partnership with the pharmaceutical company Novo Nordisk A/S. Investors allege that Hims failed to adequately disclose vital information about its business dealings with Novo, especially concerning the successful marketing of the weight-loss drug Wegovy.

Key allegations include:
1. The establishment of a collaboration between Hims and Novo that would support continued access to Wegovy for Hims users.
2. Misrepresentation regarding the branding and offerings of compounded semaglutide products.
3. Assurances about the partnership that misled investors about Hims' growth prospects and product availability.

As the truthful details about these partnerships came to light, it led to significant financial repercussions for investors, who claim damages as a result.

The Rosen Law Firm's Track Record

The Rosen Law Firm prides itself on its extensive experience in handling securities class actions. Over the years, the firm has successfully recovered hundreds of millions of dollars for investors and holds a remarkable history of settlements. Notably, in 2019 alone, the firm secured over $438 million for its clients. Its founding partner, Laurence Rosen, has gained recognition in the legal community for leadership within the plaintiffs' bar, confirming the firm’s dedication to achieving just outcomes for its clients.

Important Reminders

• - A class has not yet been certified, so participation in the class action depends on timely submissions by interested investors.
• - Being a lead plaintiff means assuming the role of a representative for other class members, guiding the litigation process.
• - Investors also have the option to remain as absent class members, should they choose not to engage actively at this stage.

Conclusion

For investors in Hims & Hers Health, Inc., this class action lawsuit represents a critical opportunity to recover losses stemming from alleged securities fraud. With the deadline to act fast approaching, those who qualify should take immediate steps to participate. Keeping abreast of updates from the Rosen Law Firm via LinkedIn, Twitter, or Facebook can provide additional insights into the developments of this case.